Cargando…

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial

This phase Ib study compared the effects of AZD9977, a selective mineralocorticoid receptor modulator with predicted low hyperkalemia risk, with spironolactone on serum potassium (sK(+)) in patients with heart failure (HF) with preserved or mildly reduced ejection fraction (EF; ≥40%), and renal impa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Squire, Iain B., Gabrielsen, Anders, Greasley, Peter J., Wernevik, Linda, Hartleib‐Geschwindner, Judith, Holden, Julie, Johansson, Susanne, Rudvik, Anna, Sánchez, José, Bamberg, Krister, Melin, Johanna, Whittaker, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579384/ https://www.ncbi.nlm.nih.gov/pubmed/35971596 http://dx.doi.org/10.1111/cts.13377

Ejemplares similares

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
por: Bamberg, Krister, et al.
Publicado: (2019)

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
por: Whittaker, Andrew, et al.
Publicado: (2019)

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
por: Bamberg, Krister, et al.
Publicado: (2018)

Electrolyte handling in the isolated perfused rat kidney: demonstration of vasopressin V2-receptor-dependent calcium reabsorption
por: Bamberg, Krister, et al.
Publicado: (2020)

Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment
por: Choy, Manting, et al.
Publicado: (2022)

Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice
por: Palacios-Ramirez, Roberto, et al.
Publicado: (2022)

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
por: Zhou, Hui‐min, et al.
Publicado: (2022)

Outcomes of Spironolactone Withdrawal in Dilated Cardiomyopathy With Improved Ejection Fraction
por: Chen, Yanjia, et al.
Publicado: (2021)

Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
por: Tsujimoto, Tetsuro, et al.
Publicado: (2020)

A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction
por: Belkin, Mark N., et al.
Publicado: (2021)

The Utility of Potassium Monitoring in Gender-Diverse Adolescents Taking Spironolactone
por: Millington, Kate, et al.
Publicado: (2019)

Effects of spironolactone in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
por: Li, Shuai, et al.
Publicado: (2018)

SUN-242 The Utility of Potassium Monitoring in Transgender Adolescents Taking Spironolactone
por: Millington, Kate, et al.
Publicado: (2019)

The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone
por: Hayes, Hailey, et al.
Publicado: (2022)

SAT379 Potassium Levels in Women with PCOS Using Spironolactone for Long-term
por: Oliveira, Thais Areias, et al.
Publicado: (2023)

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction
por: Enzan, Nobuyuki, et al.
Publicado: (2020)

Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials
por: Xiang, Yajie, et al.
Publicado: (2019)

Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2015)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan
por: Makhlough, Atieh, et al.
Publicado: (2014)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction
por: Inghardt, Tord, et al.
Publicado: (2022)

Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial
por: Neefs, Jolien, et al.
Publicado: (2019)

Poorer Exercise Accommodation of Regional Systolic Myocardial Motion after Spironolactone Treatment in Heart Failure Patients with Preserved Ejection Fraction and Ventricular Dyssynchrony
por: Yu, Chih-Chieh, et al.
Publicado: (2021)

Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
por: Schnelle, Moritz, et al.
Publicado: (2021)

Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease------Balance of efficacy and risk
por: Li, Jun-Feng, et al.
Publicado: (2023)

Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials
por: Kresoja, Karl-Patrik, et al.
Publicado: (2023)

Correction to “Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction”
por: Inghardt, Tord, et al.
Publicado: (2022)

ODP425 Potassium Level Trends in Trans Females Using Spironolactone: A Retrospective Chart Review
por: Gupta, Pranav, et al.
Publicado: (2022)

IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial
por: Shantsila, Eduard, et al.
Publicado: (2016)

Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction
por: Ortega‐Paz, Luis, et al.
Publicado: (2022)

Effectiveness of Spironolactone in Terms of Galectin-3 Levels in Patients with Heart Failure with a Reduced Ejection Fraction in the Vietnamese Population
por: Tran, Son Kim, et al.
Publicado: (2023)

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction
por: Nelander, Karin, et al.
Publicado: (2021)

Spironolactone-Induced Unilateral Gynecomastia
por: Veeregowda, Sahana Hadihalli, et al.
Publicado: (2018)

Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS‐AF Trial
por: Shantsila, Eduard, et al.
Publicado: (2020)

Plasma P‐selectin is a predictor of mortality in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2021)

Prevalence of right ventricular dysfunction and prognostic significance in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2020)

Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management
por: Kanagala, Prathap, et al.
Publicado: (2020)

Intra-study and inter-technique validation of cardiovascular magnetic resonance imaging derived left atrial ejection fraction as a prognostic biomarker in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2020)

Effect of spironolactone on pain responses in mice
por: Abdel-Salam, Omar M.E., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8n79nv02tt3bmkspo8hbo04eh8